Comparative evaluation of anticoagulant prophylaxis regimens in patients with malignant tumors of the pelvic organs in the perioperative period

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To conduct a comparative analysis of the impact of different anticoagulant therapy regimens on the dynamics of laboratory markers of the hemostasis system (D-dimer, thrombin-antithrombin complex [TAC], prothrombin fragments F1+2) and the frequency of thrombohemorrhagic complications in the perioperative period in patients with malignant neoplasms of the pelvic organs.

Materials and methods. A prospective, comparative, randomized, interventional study was conducted involving 964 patients with squamous cell carcinoma of the cervix, endometrial cancer, ovarian cancer, and squamous cell carcinoma of the vulva. All patients were subject to radical surgical treatment and were randomized into four groups depending on the anticoagulant therapy regimen: Groups I and II received low molecular weight heparin (LMWH) 10 and 1 day before surgery and then 10 days after surgery, respectively; Groups III and IV – only in the postoperative period (LMWH and unfractionated heparin, respectively). The comparison group (n=75) did not receive anticoagulant prophylaxis. To assess the activation of the coagulation cascade and fibrinolysis, quantitative methods for determining D-dimer, TAC complex, and F1+2 fragments were used. Statistical processing was performed using the Mann–Whitney criterion (p<0.05).

Results. In the study group, the incidence of deep vein thrombosis was 3.3–4.3%, pulmonary embolism – 1.1%, while in the comparison group these figures reached 13.3 and 6.7%, respectively (p<0.01). In groups I and II, no cases of moderate bleeding were recorded in the postoperative period. The most pronounced decrease in hemostasis markers (D-dimer, TAC, F1+2) was observed in group I, where LMWH was used 10 days before surgery. In the comparison group, on the contrary, persistent hypercoagulation with wave-like dynamics of markers and their significantly higher values throughout the postoperative observation period was revealed.

Conclusion. Preoperative administration of LMWH provides a significant reduction in the risk of thrombotic complications and promotes rapid normalization of hemostasis parameters while maintaining a high safety profile. The absence of anticoagulant prophylaxis is associated with pronounced activation of the coagulation system and a higher risk of deep vein thrombosis and pulmonary embolism in oncogynecological patients in the postoperative period.

Full Text

Restricted Access

About the authors

А. Vorobеv

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Author for correspondence.
Email: antoninasolopova@yandex.ru
ORCID iD: 0000-0002-4509-9281
SPIN-code: 5806-7062

Candidate of Medical Science, Professor

Russian Federation

A. Solopova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: antoninasolopova@yandex.ru
ORCID iD: 0000-0002-7456-2386
SPIN-code: 5278-0465

MD

Russian Federation

V. Bitsadze

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: antoninasolopova@yandex.ru
ORCID iD: 0000-0001-8404-1042
SPIN-code: 5930-0859

MD, Professor of the Russian Academy of Sciences

Russian Federation

R. Mirzov

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: antoninasolopova@yandex.ru
ORCID iD: 0009-0001-6691-0387
Russian Federation

A. Sosnyagov

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: antoninasolopova@yandex.ru
ORCID iD: 0009-0007-4626-1897
Russian Federation

A. Ivanov

S.S. Yudin City Clinical Hospital, Moscow Healthcare Department

Email: antoninasolopova@yandex.ru
ORCID iD: 0000-0003-1115-3144

Candidate of Medical Science

Russian Federation

D. Utkin

S.S. Yudin City Clinical Hospital, Moscow Healthcare Department

Email: antoninasolopova@yandex.ru
ORCID iD: 0000-0002-6620-2073
SPIN-code: 2368-7127

Candidate of Medical Science, Professor

Russian Federation

A. Makatsariya

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: antoninasolopova@yandex.ru
ORCID iD: 0000-0001-7415-4633
SPIN-code: 7538-2966

Academician of the Russian Academy of Sciences, MD

Russian Federation

References

  1. Falanga A., Russo L., Milesi V. et al. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 2017; 118: 79–83. doi: 10.1016/j.critrevonc.2017.08.003
  2. Hisada Y., Mackman N. Mechanisms of cancer-associated thrombosis. Res Pract Thromb Haemost. 2023; 7 (3): 100123. doi: 10.1016/j.rpth.2023.100123
  3. Макацария А.Д., Воробьев А.В. Гемостазиологические аспекты опухолевого роста. Акушерство и гинекология. 2016; 9: 28–36 [Makatsaria A.D., Vorobyev A.V. Hemostasiological aspects of tumor growth. Obstetrics and Gynecology. 2016; 9: 28–36 (in Russ.)]. doi: 10.18565/aig.2016.9.28-36
  4. Lavikainen L.I., Guyatt G.H., Luomaranta A.L. et al. Risk of thrombosis and bleeding in gynecologic cancer surgery: systematic review and meta-analysis. Am J Obstet Gynecol. 2024; 230 (4): 403–16. doi: 10.1016/j.ajog.2023.10.006
  5. Sevestre M.A., Soudet S. Epidemiology and risk factors for cancer-associated thrombosis. J Med Vasc. 2020; 45 (6S): 6S3-6S7. doi: 10.1016/S2542-4513(20)30513-7
  6. Girardi L., Wang T.F., Ageno W. et al. Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism. Arterioscler Thromb Vasc Biol. 2023; 43 (6): 824–31. doi: 10.1161/ATVBAHA.123.318779
  7. Falanga A., Ay C., Di Nisio M. et al. ESMO Guidelines Committee. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023; 34 (5): 452–67. doi: 10.1016/j.annonc.2022.12.014
  8. Cohen A., Lim C.S., Davies A.H. Venous Thromboembolism in Gynecological Malignancy. Int J Gynecol Cancer. 2017; 27 (9): 1970–8. doi: 10.1097/IGC.0000000000001111
  9. Ma S.G., Hu J., Huang Y. The risk factors for perioperative venous thromboembolism in patients with gynecological malignancies: A meta-analysis. Thromb Res. 2020; 196: 325–34. doi: 10.1016/j.thromres.2020.09.019
  10. Ali N.T., Young A. Treatment and secondary prophylaxis of venous thromboembolism in cancer patients. Support Care Cancer. 2022; 30 (10): 8519–26. doi: 10.1007/s00520-022-07135-x
  11. Streiff M.B., Holmstrom B., Angelini D. et al. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19 (10): 1181–201. doi: 10.6004/jnccn.2021.0047
  12. Boccaccio C., Comoglio P.M. A functional role for hemostasis in early cancer development. Cancer Res. 2005; 65 (19): 8579–82. doi: 10.1158/0008-5472.CAN-05-2277
  13. Ivankovic V., Delisle M., Noureldin A. et al. "To bleed or to clot, that is the question"-the benefit of a procedure-specific risk tool to guide perioperative anticoagulation. Hepatobiliary Surg Nutr. 2024; 13 (6): 1058–61. doi: 10.21037/hbsn-24-608
  14. Shaw J.R., Douketis J., Le Gal G. et al. Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. J Thromb Haemost. 2019; 17 (7): 1171–8. doi: 10.1111/jth.14468
  15. Wagner J., Lock J.F., Kastner C. et al. Perioperative management of anticoagulant therapy. Innov Surg Sci. 2019; 4 (4): 144–51. doi: 10.1515/iss-2019-0004
  16. Junqueira D.R., Zorzela L.M., Perini E. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev. 2017; 4 (4): CD007557. doi: 10.1002/14651858.CD007557.pub3
  17. Matar C.F., Kahale L.A., Hakoum M.B. et al. Anticoagulation for perioperative thromboprophylaxis in people with cancer. Cochrane Database Syst Rev. 2018; 7 (7): CD009447. doi: 10.1002/14651858.CD009447.pub3
  18. Kuderer N.M., Lyman G.H. Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res. 2014; 133 Suppl 2(02): S122-7. doi: 10.1016/S0049-3848(14)50021-7
  19. Khorana A.A., DeSancho M.T., Liebman H. et al. Prediction and Prevention of Cancer-Associated Thromboembolism. Oncologist. 2021; 26 (1): e2-e7. doi: 10.1002/onco.13569
  20. Takahashi Y., Fujiwara H., Yamamoto K. et al. GOTIC-VTE Trial Investigators. Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial. J Gynecol Oncol. 2024; 35 (4): e37. doi: 10.3802/jgo.2024.35.e37
  21. Barber E.L., Clarke-Pearson D.L. Prevention of venous thromboembolism in gynecologic oncology surgery. Gynecol Oncol. 2017; 144 (2): 420–7. doi: 10.1016/j.ygyno.2016.11.036
  22. Pabinger I., Thaler J., Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013; 122 (12): 2011–8. doi: 10.1182/blood-2013-04-46014

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Study groups in the perioperative period

Download (67KB)

Copyright (c) 2025 Russkiy Vrach Publishing House